Top Page
Cyclopharm Limited
(Sydney:CYC)
Cyclopharm Limited (CYC) vs. iShares MSCI Australia ETF (EWA)
Cyclopharm Limited Business Overview & Revenue Model
Cyclopharm Limited Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.57M | 27.14M | 23.22M | 17.70M | 14.68M |
| Gross Profit | 17.93M | 4.50M | 5.94M | 3.20M | 2.08M |
| EBITDA | -13.69M | -3.03M | -5.36M | -4.19M | -4.86M |
| Net Income | -13.20M | -4.70M | -6.61M | -5.04M | -6.04M |
Balance Sheet | |||||
| Total Assets | 62.13M | 45.91M | 49.54M | 55.74M | 28.28M |
| Cash, Cash Equivalents and Short-Term Investments | 20.57M | 11.73M | 20.30M | 29.25M | 1.87M |
| Total Debt | 8.29M | 4.23M | 4.33M | 4.51M | 4.71M |
| Total Liabilities | 19.40M | 13.65M | 13.01M | 12.67M | 11.16M |
| Stockholders Equity | 42.73M | 32.26M | 36.54M | 43.07M | 17.12M |
Cash Flow | |||||
| Free Cash Flow | -13.55M | -7.74M | -8.21M | -2.79M | -9.47M |
| Operating Cash Flow | -12.57M | -7.20M | -6.66M | -1.63M | -8.93M |
| Investing Cash Flow | -971.86K | -508.47K | -1.55M | -1.16M | -874.19K |
| Financing Cash Flow | 22.22M | -1.02M | -725.64K | 30.17M | -985.96K |
Cyclopharm Limited Technical Analysis
Cyclopharm Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$203.57M | ― | -4.06% | ― | 20.36% | 64.81% | |
60 Neutral | AU$56.70M | ― | -8.08% | ― | -5.62% | -225.71% | |
49 Neutral | AU$148.37M | ― | -58.61% | ― | ― | -74.88% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% | |
45 Neutral | AU$120.03M | ― | -35.20% | ― | 4.68% | -155.42% | |
| ― | $70.78M | ― | -51.08% | ― | ― | ― | |
41 Neutral | AU$121.04M | ― | -52.37% | ― | 471.29% | -4.58% |
Cyclopharm Limited Corporate Events
Cyclopharm Limited has appointed Thomas Lukas as Vice President of Sales in the United States to lead a new Business Development Team, aiming to accelerate sales of Technegas in the U.S. market. This strategic hire is part of Cyclopharm’s multi-stage U.S. sales strategy, which includes expanding their sales operations and increasing the adoption of Technegas across U.S. hospital systems. The company is capitalizing on the growing awareness of Technegas’ clinical value, supported by established reimbursement and federal engagements, as well as strong clinical advocacy.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has secured a five-year patent extension for its Technegas® Kit in the United States, extending exclusivity until 2031. This extension provides a significant competitive advantage in the U.S. market, allowing Cyclopharm to capitalize on the commercial and clinical potential of Technegas® without the threat of generic competition. The extension underscores the strong clinical profile of Technegas® and supports Cyclopharm’s strategic efforts to expand its market presence and innovation in pulmonary imaging technologies.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited announced that all resolutions proposed at its Annual General Meeting on May 30, 2025, were successfully passed. This includes approvals related to remuneration reports, director re-elections, and performance rights grants, which reflect strong shareholder support and may positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has released a presentation containing forward-looking statements and projections about its future financial performance and market conditions. The company emphasizes that these projections are based on assumptions and are subject to uncertainties, and it does not guarantee their accuracy. The release highlights the company’s cautious approach to future predictions and its focus on managing stakeholder expectations.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited reported a record year in 2024, marked by the commencement of commercial sales in the United States following FDA approval. The company’s revenue reached $27.6 million, with Technegas sales contributing significantly. Despite a loss after tax of $13.2 million, Cyclopharm’s strategic expansion into the US market and its growing third-party distribution business are set to drive future growth. The company’s focus on expanding the use of Technegas for conditions beyond pulmonary embolism, such as COPD and asthma, indicates potential for accessing larger markets and achieving long-term growth.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has announced its Annual General Meeting, scheduled for May 30, 2025, in Kingsgrove, NSW. The meeting will address several key resolutions, including financial statements, director re-election, and approval of performance rights and remuneration. This meeting is crucial for stakeholders as it will determine strategic decisions impacting the company’s governance and financial strategies.